Topics

Glioblastoma | Diagnosis | Magnetic resonance imaging | Differentiation Progression-Pseudoprogression and Progression-Necrosis

Home > Publications > Topics > Glioblastoma > Diagnosis > Magnetic resonance imaging > Differentiation Progression-Pseudoprogression

Khalaj K, Jacobs MA, Zhu JJ, Esquenazi Y, Hsu S, Tandon N, Akhbardeh A, Zhang X, Riascos R, Kamali A.
The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.
Cancers (Basel). 2024 Jul 2;16(13):2440. doi: 10.3390/cancers16132440. PMID: 39001500. Observational study. ˍ

van Dorth D, Croese RJI, Jiang FY, Schmitz-Abecassis B, Taphoorn MJB, Smits M, Dirven L, van Osch MJP, de Bresser J, Koekkoek JAF.
Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Neurooncol Pract. 2024 Oct 15;12(2):281-290. doi: 10.1093/nop/npae099. PMID: 40110054. Observational study. ˍ

Var V, Leu SM, Rommers N, Psychogios MN, Cordier D, Todea RA.
Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI.
J Neuroradiol. 2025 May 24;52(4):101354. doi: 10.1016/j.neurad.2025.101354. PMID: 40419180. Observational study. ˍ

Hoosemans LJN, Panayotopoulos LF, van Kuijk SMJ, Verduin M, Anten MHME, Pasmans RCOS, Schellekens JM, Huijs SMH, Verhoeff SR, van den Berkmortel FWPJ, Steggink LC, Ackermans L, Schijns OEMG, Teernstra OPM, Hovinga K, Beckervordersandforth JC, Compter I, Eekers DBP, Postma AA, Vooijs MA, Broen MPG, Hoeben A.
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.
J Neurooncol. 2025 Oct 24;176(1):42. doi: 10.1007/s11060-025-05299-0. PMID: 41134378. Observational study. ˍ

Zeyen T, Krause I, Decker A, Kroh F, Regnery S, Weller J, Schaefer N, Zidan M, Potthoff AL, Schneider M, Friker LL, Keupp J, Katemann C, Layer JP, Schaub C, Gkika E, Vatter H, Pietsch T, Radbruch A, Herrlinger U, Paech D.
Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.
Neuro Oncol. 2025 Nov 13:noaf261. doi: 10.1093/neuonc/noaf261. PMID: 41233976. Observational study. ˍ